| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| N Sicolo, C Martini, S Ferla, J Roggenkamp, R Vettor, C De Palo, G Federspi. [Analgesic effect of Sandostatin (SMS 201-995) in acromegaly headache]. Minerva endocrinologica. vol 15. issue 1. 1991-02-28. PMID:2274013. |
somatostatin analogue (sandostatin; sms 201-995) is utilized as a therapy in acromegaly because of its efficiency in inhibiting gh secretion; it induces some clinical improvements, such as headache remission in acromegalic patient, which seem to be unrelated to gh normalization. |
1991-02-28 |
2023-08-11 |
Not clear |
| N Sicolo, C Martini, S Ferla, J Roggenkamp, R Vettor, C De Palo, G Federspi. [Analgesic effect of Sandostatin (SMS 201-995) in acromegaly headache]. Minerva endocrinologica. vol 15. issue 1. 1991-02-28. PMID:2274013. |
our results confirm an important and rapid analgesis effect of sandostatin on acromegaly headache unrelated to gh normalization. |
1991-02-28 |
2023-08-11 |
Not clear |
| A Piovesan, M Terzolo, G Borretta, M Torta, T Buniva, G Osella, P Paccotti, A Angel. Circadian profile of serum melatonin in Cushing's disease and acromegaly. Chronobiology international. vol 7. issue 3. 1991-02-19. PMID:2268888. |
we evaluated the circadian profiles of serum melatonin (mt) and cortisol in 6 patients with cushing's disease while those of serum mt and gh were evaluated in 8 patients with acromegaly. |
1991-02-19 |
2023-08-11 |
human |
| J Girard, T Fischer-Wasel. Measurement of urinary growth hormone. A noninvasive method to assess the 'growth hormone status'. Hormone research. vol 33 Suppl 4. 1991-01-07. PMID:2245965. |
using pharmacological tests or gh profiles, gh deficiency or active acromegaly can be diagnosed. |
1991-01-07 |
2023-08-11 |
Not clear |
| B A Bengtsson, R J Brummer, I Bosaeu. Growth hormone and body composition. Hormone research. vol 33 Suppl 4. 1991-01-07. PMID:2245966. |
the changes in cell mass, body fat and extracellular water observed in acromegaly suggest different dose-response relationships between gh and these parameters. |
1991-01-07 |
2023-08-11 |
human |
| E A van der Veen, J C Netelenbo. Growth hormone (replacement) therapy in adults: bone and calcium metabolism. Hormone research. vol 33 Suppl 4. 1991-01-07. PMID:2245971. |
however, gh excess, as seen in acromegaly, does not result in increased bone mass. |
1991-01-07 |
2023-08-11 |
human |
| N Kuzuya, K Inoue, M Ishibashi, Y Murayama, Y Koide, K Ito, T Yamaji, K Yamashit. Endocrine and immunohistochemical studies on thyrotropin (TSH)-secreting pituitary adenomas: responses of TSH, alpha-subunit, and growth hormone to hypothalamic releasing hormones and their distribution in adenoma cells. The Journal of clinical endocrinology and metabolism. vol 71. issue 5. 1990-12-10. PMID:1699960. |
1) had elevated serum gh levels with clinical evidence of acromegaly. |
1990-12-10 |
2023-08-11 |
Not clear |
| H Lunt, A J Tucker, H Bullen, C Gibbs, T J Wilki. Overnight urinary growth hormone measurement in the diagnosis of acromegaly. Clinical endocrinology. vol 33. issue 2. 1990-12-05. PMID:2225479. |
we investigated the diagnostic potential of overnight urinary gh excretion in acromegaly, using a recently developed enzyme-linked immunosorbent assay. |
1990-12-05 |
2023-08-11 |
human |
| H Lunt, A J Tucker, H Bullen, C Gibbs, T J Wilki. Overnight urinary growth hormone measurement in the diagnosis of acromegaly. Clinical endocrinology. vol 33. issue 2. 1990-12-05. PMID:2225479. |
the range for total overnight urinary gh in control subjects was 0.75-21.75 microu and two of the nine patients with untreated acromegaly had gh measurements within this range. |
1990-12-05 |
2023-08-11 |
human |
| H Lunt, A J Tucker, H Bullen, C Gibbs, T J Wilki. Overnight urinary growth hormone measurement in the diagnosis of acromegaly. Clinical endocrinology. vol 33. issue 2. 1990-12-05. PMID:2225479. |
lack of complete discrimination between control subjects and acromegalic patients limits the usefulness of a single overnight urinary gh measurement as a screening test for acromegaly. |
1990-12-05 |
2023-08-11 |
human |
| F Roelfsema, H de Boer, M Frölic. The influence of octreotide treatment on pulsatile growth hormone release in acromegaly. Clinical endocrinology. vol 33. issue 2. 1990-12-05. PMID:2225485. |
this study demonstrates the pulsatile release of gh in active acromegaly both before and during octreotide therapy. |
1990-12-05 |
2023-08-11 |
Not clear |
| A Shimatsu, N Hattori, T Tanoh, H Assadian, H Imur. [Clinical application of a sensitive immunoradiometric assay for human growth hormone]. Nihon Naibunpi Gakkai zasshi. vol 66. issue 7. 1990-10-18. PMID:2118864. |
determination by sensitive irma of gh responses during oral glucose loading is useful for evaluating the activity of postoperative acromegaly. |
1990-10-18 |
2023-08-11 |
human |
| F Slowik, I Fazekas, K Bálint, L Gazsó, E Pásztor, S Czirják, K Lapi. Intrasellar hamartoma associated with pituitary adenoma. Acta neuropathologica. vol 80. issue 3. 1990-10-16. PMID:2399812. |
the histological, ultrastructural and immunocytochemical features are reported of an intrasellar neuronal and lipomatous hamartoma associated with pituitary growth hormone (gh) cell adenoma and acromegaly. |
1990-10-16 |
2023-08-11 |
Not clear |
| M C Gelato, E Oldfield, D L Loriaux, G R Merria. Pulsatile growth hormone secretion in patients with acromegaly and normal men: the effects of growth hormone-releasing hormone infusion. The Journal of clinical endocrinology and metabolism. vol 71. issue 3. 1990-10-09. PMID:2118536. |
twenty-four gh secretory patterns were studied before and during continuous infusions of ghrh in six patients with active acromegaly and in six normal adult men. |
1990-10-09 |
2023-08-11 |
human |
| M C Gelato, E Oldfield, D L Loriaux, G R Merria. Pulsatile growth hormone secretion in patients with acromegaly and normal men: the effects of growth hormone-releasing hormone infusion. The Journal of clinical endocrinology and metabolism. vol 71. issue 3. 1990-10-09. PMID:2118536. |
during continuous 24-h infusions of ghrh, the normal subjects continued to show a diurnal variation in gh release, but gh pulse frequency increased to a rate (11.7 +/- 1.4 pulses/24 h) very similar to that of the patients with acromegaly. |
1990-10-09 |
2023-08-11 |
human |
| M C Gelato, E Oldfield, D L Loriaux, G R Merria. Pulsatile growth hormone secretion in patients with acromegaly and normal men: the effects of growth hormone-releasing hormone infusion. The Journal of clinical endocrinology and metabolism. vol 71. issue 3. 1990-10-09. PMID:2118536. |
some of the patients with acromegaly showed a progressive decline in gh levels during the infusion period, suggesting desensitization or exhaustion of releaseable stores; however, gh levels remained above basal values in all patients. |
1990-10-09 |
2023-08-11 |
human |
| M C Gelato, E Oldfield, D L Loriaux, G R Merria. Pulsatile growth hormone secretion in patients with acromegaly and normal men: the effects of growth hormone-releasing hormone infusion. The Journal of clinical endocrinology and metabolism. vol 71. issue 3. 1990-10-09. PMID:2118536. |
these results indicate that gh release is episodic under basal conditions and during continuous ghrh infusion in both acromegalic and normal subjects, indicating the importance of other modulators of gh release, such as somatostatin, which may remain pulsatile even in acromegaly. |
1990-10-09 |
2023-08-11 |
human |
| S Harve. "Paradoxical" growth hormone secretion in acromegaly: an avian model? The Journal of experimental zoology. Supplement : published under auspices of the American Society of Zoologists and the Division of Comparative Physiology and Biochemistry. vol 4. 1990-09-24. PMID:1974792. |
acromegaly is a pathological human condition resulting from an excess of growth hormone (gh) secretion in adults. |
1990-09-24 |
2023-08-11 |
human |
| Y F Shi, A G Harris, X F Zhu, J Y Den. Clinical and biochemical effects of incremental doses of the long-acting somatostatin analogue SMS 201-995 in ten acromegalic patients. Clinical endocrinology. vol 32. issue 6. 1990-09-20. PMID:2200620. |
ten patients (seven women, three men) with active acromegaly, five previously treated and five newly diagnosed, were included in an open-label prospective trial of 3 daily subcutaneous injections of the long-acting somatostatin analogue sms 201-995 (sandostatin) at increasing doses in order to obtain maximum growth hormone (gh) suppression. |
1990-09-20 |
2023-08-11 |
Not clear |
| K Mukad. The natural course of growth hormone-secreting pituitary adenomas after surgery alone--clinical significance of the growth hormone response to thyrotropin-releasing hormone and luteinizing hormone-releasing hormone. Neurologia medico-chirurgica. vol 30. issue 4. 1990-09-18. PMID:1696695. |
the clinical significance of abnormal growth hormone (gh) secretion in response to thyrotropin-releasing hormone (trh) and luteinizing hormone-releasing hormone (lhrh) was studied in 52 patients with acromegaly due to gh secreting pituitary adenomas treated by trans-sphenoidal microsurgery. |
1990-09-18 |
2023-08-11 |
Not clear |